60mg-30 (Mm1)
Raloxifene Hydrochloride Tablet, Film Coated
Product Images NDC 76282-256
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Raloxifene Hydrochloride (NDC 76282-256). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Exelan Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Raloxifene Graph
This appears to be a report analyzing bone mineral density changes in subjects with placebo, Raloxitene, and CE over 24 months. The focus seems to be on total hip percentage changes from baseline. The report utilized instant 10 treatment analysis and fast observation carried forward methods. There is also a figure depicting the total hip bone mineral density mean percentage change from baseline over months after randomization. The report seems to be related to the effects of GE conjugated estrogens, but it is not entirely clear.*
Structure (Structure)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
